skip to Main Content

Dougan Discusses Augmenting T-Cell Activity in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Pancreatic ductal adenocarcinoma (PDAC) is rapidly metastatic and has proven to be largely unresponsive to current checkpoint blockade, said Stephanie K. Dougan, PhD. However, ongoing research aimed at priming tumor-specific T cells may lead to increased immunogenicity in pancreatic cancer, as well as other poorly immunogenic malignancies.

“We’ve been thinking about ways to augment T-cell priming to poorly immunogenic tumors,” said Dougan. “Checkpoint blockade operates by de-inhibiting T cells. You can take the breaks off of the immune system, but this means that you have T cells there to begin with. Read more . . . 


Back To Top